Palvella Reports Positive Phase 3 Data for QTORIN

Palvella Therapeutics ( (PVLA) ) has shared an announcement.

On February 24, 2026, Palvella Therapeutics reported positive topline data from its Phase 3 SELVA study of once-daily QTORIN 3.9% rapamycin gel in patients with microcystic lymphatic malformations, a rare and debilitating genetic disease with no approved therapies. The trial met its primary and all secondary efficacy endpoints with high statistical significance, showed substantial clinician-assessed improvement in 95% of evaluable participants aged six and older at Week 24, and demonstrated a favorable safety profile with only mild to moderate treatment-related adverse events and low systemic rapamycin exposure.

The single-arm, baseline-controlled study enrolled 51 participants aged three and above and exceeded its target enrollment across leading U.S. vascular anomaly centers, with 88% completing the 24-week efficacy period and 98% of eligible participants opting into the extension phase. These results underpin Palvella’s plan to file a New Drug Application in the second half of 2026 for QTORIN rapamycin, which, if approved, could become the first FDA-sanctioned treatment and potential standard of care for an estimated 30,000 individuals with microcystic lymphatic malformations in the U.S., reinforcing the company’s positioning as a leading rare disease biopharma player.

The most recent analyst rating on (PVLA) stock is a Buy with a $205.00 price target. To see the full list of analyst forecasts on Palvella Therapeutics stock, see the PVLA Stock Forecast page.

Spark’s Take on PVLA Stock

According to Spark, TipRanks’ AI Analyst, PVLA is a Neutral.

The score is held down primarily by weak financial performance (no current revenue, ongoing losses, and persistent cash burn) and bearish technical signals. Offsetting this, corporate events are notably positive with encouraging Phase 2 data and clear near-term clinical/regulatory catalysts, but this does not fully overcome the current fundamentals and trend.

To see Spark’s full report on PVLA stock, click here.

More about Palvella Therapeutics

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations that currently lack U.S. Food and Drug Administration-approved treatments. The company is advancing its QTORIN™ rapamycin platform in multiple indications driven by hyperactivation of the mTOR pathway, including cutaneous venous malformations and clinically significant angiokeratomas.

Average Trading Volume: 274,863

Technical Sentiment Signal: Buy

Current Market Cap: $942.2M

See more data about PVLA stock on TipRanks’ Stock Analysis page.